Crossmark

153Sm-EDTMP Therapy as a Therapeutic Option in Mixed Skeletal Metastases from Renal Cell Carcinoma with Disease Progression Post 2nd Line Tyrosine Kinase Therapy

Crossref DOI link: https://doi.org/10.1007/s13139-025-00938-w

Published Online: 2025-07-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kumar, Srinivas Ananth https://orcid.org/0009-0000-7371-1215
Srivastava, Madhur Kumar
License Information

Text and Data Mining valid from 2025-07-31

Version of Record valid from 2025-07-31
More Information

Article History

Received: 11 May 2025

Revised: 2 July 2025

Accepted: 14 July 2025

First Online: 31 July 2025

Declarations

:

: The institutional review board at our institution approved this retrospective study, and the requirement to obtain informed consent was waived.

: In our institution, IRB approval is waived for case reports or similar research formats. Nonetheless, this study was conducted in accordance with the 2013 Helsinki Declaration and its later amendments or comparable ethical standards.

: The institutional review board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.

: Authors did not use generative AI in writing except for checking grammar, spelling, references, etc.

: Srinivas Ananth Kumar and Madhur Kumar Srivastava declare that they have no conflict of interest.

Document is current

Any future updates will be listed below